Back to results
US 9,284,309 B2Granted
Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation
AssigneeNeuropore Therapies, Inc.
InventorWolfgang Wrasidlo
Life of this patent
Estimating the term…
Abstract
The present invention relates to certain di- and tri-heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, and multiple system atrophy.
Claims20
A compound of Formula I:
- wherein
- X, Y, and Z are each independently CH or N;
- R1 is H, C1-6alkyl, or C3-7cycloalkyl;
- R2 is H, C1-6alkyl, or C3-7cycloalkyl;
- each R3 is independently halogen, hydroxy, C1-4alkoxy, cyano, amino, or —CF3;
- n is 0, 1, or 2;
- and
- A moiety is:
- (a) a 5-membered heteroaryl ring substituted with C1-6alkyl;
- or
- wherein W is a 5-membered heteroaryl ring, —C(O)NHNHC(O)—, —C(NH)NH—, or —C(O)NHNH—;
- and
- R4 is H or C1-6alkyl;
- or a pharmaceutically acceptable salt thereof.
11 more elements
A compound selected from the group consisting of:
- and pharmaceutically acceptable salts thereof.
A pharmaceutical composition comprising (a) at least one compound of Formula I:
- wherein
- X, Y, and Z are each independently CH or N;
- R1 is H, C1-6alkyl, or C3-7cycloalkyl;
- R2 is H, C1-6alkyl, or C3-7cycloalkyl;
- each R3 is independently halogen, hydroxy, C1-4alkoxy, cyano, amino, or —CF3;
- n is 0, 1, or 2;
- and
- A moiety is:
- (a) a 5-membered heteroaryl ring substituted with C1-6alkyl;
- or
- wherein W is a 5-membered heteroaryl ring, —C(O)NHNHC(O)—, —C(NH)NH—, or —C(O)NHNH—;
- and
- R4 is H or C1-6alkyl;
- or a pharmaceutically acceptable salt thereof, and
- (b) a pharmaceutically acceptable excipient.
12 more elements
Dependencies are inferred from the claim text.